First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study.
about
Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive reviewHepatocellular carcinoma: From clinical practice to evidence-based treatment protocolsMultimodal treatment of hepatocellular carcinoma on cirrhosis: an updateRecent advances in multidisciplinary management of hepatocellular carcinomaManagement of hepatocellular carcinoma with portal vein thrombosisUltrasound Elastography Used for Preventive Non-Invasive Screening in Early Detection of Liver FibrosisSelection and management of hepatocellular carcinoma patients with sorafenib: recommendations and opinions from an Italian liver unit.Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08-20.Multidisciplinary management of hepatocellular carcinoma in clinical practice.Relationship of ethnicity and overall survival in patients treated with sorafenib for advanced hepatocellular carcinoma.Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinomaDownregulation of signal transducer and activator of transcription 3 by sorafenib: a novel mechanism for hepatocellular carcinoma therapy.GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis.Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: The jury is still out.The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations.Comparison of treatment safety and patient survival in elderly versus nonelderly patients with advanced hepatocellular carcinoma receiving sorafenib combined with transarterial chemoembolization: a propensity score matching studyComparative dosing and efficacy of sorafenib in hepatocellular cancer patients with varying liver dysfunctionHong Kong consensus recommendations on the management of hepatocellular carcinoma.Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinoma.Comparative Metabolomic Profiling of Hepatocellular Carcinoma Cells Treated with Sorafenib Monotherapy vs. Sorafenib-Everolimus Combination Therapy.Poly(lactide-co-glycolide) microspheres for MRI-monitored delivery of sorafenib in a rabbit VX2 model.The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma.Long-Term Maintenance of Complete Response after Sorafenib Treatment for Multiple Lung Metastases from Hepatocellular CarcinomaImpact of more detailed categorization of shrinkage or progression ratio at initial imaging response after sorafenib treatment in advanced hepatocellular carcinoma patients.Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data.The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring.Use of Transarterial Chemoembolization (TACE) and Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: US Regional Analysis of the GIDEON RegistrySafety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study.A phase I dose-finding study of silybin phosphatidylcholine (milk thistle) in patients with advanced hepatocellular carcinoma.Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON.Nonsurgical treatment for localized hepatocellular carcinoma.In a 'real-world', clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survival.Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinomaCombination of intra-arterial therapies and sorafenib: is there a clinical benefit?Diagnosis and treatment of hepatocellular carcinoma: An update.Sorafenib: 10 years after the first pivotal trial.Chemotherapy for hepatocellular carcinoma: The present and the future.Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world study.Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study.
P2860
P921
Q26772299-F39BC300-4044-4150-8CF4-56BFAF29F40BQ26783881-AD8A44AC-6C0B-4303-9E97-AE91DCCC1ECBQ26825172-D702747C-1F86-4F63-B8FE-DAF57C748042Q26863748-D13BEABC-B31E-4984-8279-93DF59B526ABQ26996578-B1983A7B-74B1-4D90-B1BD-B95D0143930DQ30376269-B0F019A5-B9A5-40FD-AAF2-DEFD4307BF56Q30486078-51A2C4D8-F666-4A0D-96C2-05E6EBA896EFQ33411001-12944F8E-7398-410E-802A-FF1E40E664ACQ33443438-DEAF59F0-C0E1-4C16-858E-C53363CBEBEAQ33666679-B58FF82B-9394-40ED-B310-14B5AF18D3C7Q33948042-6A586A55-94A2-400F-9835-6D5E76498D20Q34263363-9FEF8243-97BD-4492-8F14-BE62A4DFA3C0Q34467228-9D103C91-4C00-4109-A4E8-4AC30564D8E5Q34693220-7E75CB44-BB43-4802-BF95-592BA4B924AFQ34728237-0B23C8BC-B5EF-4E06-9F2E-1C367A722418Q34826535-D7FD8EF8-5DBD-4557-924E-C148F711736AQ35091836-C46B47C1-86F8-4D7D-AA60-C1FAC735C1A6Q35419331-207C5829-E563-40A9-87A3-D7C9C0C93A99Q35631295-9891D664-7C08-45E6-8C9A-E830F64F674EQ35739362-3889999B-C56A-40CD-B312-47C3C5F7C71FQ35776357-7562ED94-8602-41A9-9FE2-077850871243Q35838170-68F55EE6-7DCC-4E62-9A76-AC6FDC544FEDQ35888783-BC007CA6-C8D6-4B32-8D90-A8ECCA6F4002Q36028682-447A6B07-714F-4AE0-A8C1-872CA2645F38Q36257073-6EDBDB01-5885-46AE-B673-0978F6BCF3E5Q36325065-47FD2A2C-98E7-41D9-B305-8954B61F24FFQ36508942-F5E67070-E4D2-45CD-BE42-315887B89727Q36682439-8DE43883-F95F-4C3E-A9BA-67F60800D2CDQ36916295-314C7E6F-B70B-402D-93E7-A25E231C09F0Q37399436-43B7F2FE-C144-41F7-9F94-2CA00BC44C87Q37433645-4B5AE6A0-364F-42F8-8C82-ED822D21AED1Q37578521-7B67FB6D-DA07-4C8D-995D-007A29511832Q37640588-4FB5B517-7CF4-4065-A50F-D89105F635E7Q37696388-1C18BB0F-7049-4458-8BC9-36F621CCA53CQ38217457-84F6A3B4-0803-4234-9233-53797889255EQ38408866-5F844B1C-C621-454E-8A40-B4FC39A37974Q38544841-B5B5AE78-D2AA-4820-B1FC-8B1FCEDECC61Q38639762-A38A2A42-A896-4A5D-9E32-874D9CD0BCDDQ38830457-2D3F189B-A9EA-454F-B1CC-EC91647C2FFAQ38986591-D74E4F6B-8886-4F57-864A-AC307A4FB5AF
P2860
First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
First interim analysis of the ...... Nib) non-interventional study.
@en
First interim analysis of the GIDEON
@nl
type
label
First interim analysis of the ...... Nib) non-interventional study.
@en
First interim analysis of the GIDEON
@nl
prefLabel
First interim analysis of the ...... Nib) non-interventional study.
@en
First interim analysis of the GIDEON
@nl
P2093
P2860
P1476
First interim analysis of the ...... Nib) non-interventional study.
@en
P2093
A J Sanyal
C Papandreou
J A Marrero
J F Geschwind
J-P Bronowicki
K Nakajima
L Ladrón de Guevara
P2507
P2860
P304
P356
10.1111/J.1742-1241.2012.02940.X
P577
2012-07-01T00:00:00Z